Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

25 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

18 treatment refractory Diffuse Large B-Cell Lymphomas

ABSTRACT: Frozen biopsies collected at diagnosis from 18 DLBCLs were analyzed to find copy number events that could predict the relapse. Hybridizations were performed against a common DNA pool.

ORGANISM(S): Homo sapiens

SUBMITTER: Sylvain Mareschal

PROVIDER: E-MTAB-4496 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.

Jardin Fabrice F Ruminy Philippe P Kerckaert Jean-Pierre JP Parmentier Françoise F Picquenot Jean-Michel JM Quief Sabine S Villenet Céline C Buchonnet Gérard G Tosi Mario M Frebourg Thierry T Bastard Christian C Tilly Hervé H

Haematologica 20080220 4

<h4>Background</h4>Genomic gains and losses play a crucial role in the development of diffuse large B-cell lymphomas. High resolution array comparative genomic hybridization provides a comprehensive view of these genomic imbalances but is not routinely applicable. We developed a polymerase chain reaction assay to provide information regarding gains or losses of relevant genes and prognosis in diffuse large B-cell lymphomas.<h4>Design and methods</h4>Two polymerase chain reaction assays (multiple ...[more]

PMID: 18287131

Publication: 1/2

Similar Datasets

51 Diffuse Large B-Cell lymphomas

Project description:Frozen biopsies collected at diagnosis from 51 DLBCLs were analyzed to find recurrent copy number events in this disease. Hybridizations were performed against a common DNA pool.

2017-05-15 | E-MTAB-4497 | biostudies-arrayexpress

38 Diffuse Large B-Cell lymphomas

Project description:Frozen biopsies collected at diagnosis from 38 DLBCLs were analyzed to find recurrent copy number events in this disease. Hybridizations were performed against matching DNA samples extracted from Peripheral Blood Mononuclear Cells (PBMC).

2017-05-15 | E-MTAB-4495 | biostudies-arrayexpress

Integrative Analysis of a series of newly diagnosed Diffuse Large B-cell Lymphomas (DLBCLs)

Project description:Diffuse large B-cell lymphoma (DLBCL) is a clinically and biologically heterogeneous disease. We have characterized recurrent copy number alterations (CNAs) in a large series of primary DLBCLs with HD-SNP arrays and the GISTIC algromithm. We evaluated the associations between transcript abundance and the presence of specific CNAs by obtaining RNA profiles on the majority of the primary DLBCLs and integrating the gene expression profiles with the copy number data. High molecular weight DNA and total RNA were extracted from frozen biopsy specimens of newly diagnosed and previously untreated primary DLBCLs according to IRB-approved protocols. DLBCL diagnoses and > 80% tumor involvement were confirmed by expert hematologists. 180 primary DLBCLs and 53 normal DNA samples were profiled on Affymetrix SNP array 6.0. 169 of these primary DLBCLs were RNA profiled, 78 on Affymetrix U133A+B and 91 on U133plus2 arrays.

2012-09-12 | E-GEOD-34171 | biostudies-arrayexpress

Role of microRNAs and microRNA machinery in the pathogenesis of Diffuse large B-cell Lymphomas

2014-01-27 | GSE42906 | GEO

Gene expression profiling of diffuse large B-cell lymphomas supervised by CD5 expression

Project description:CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) has a poor prognosis and high incidence of central nervous system (CNS) relapse, even in the rituximab era. To determine the gene expression profile of CD5+ DLBCL, total RNA from 90 patients with DLBCL, including 33 CD5+ DLBCL and 57 CD5-negative (CD5-) DLBCL patients, was examined using Agilent human oligo microarrays. These cases were separated into 78 activated B-cell-like (ABC) DLBCLs and 12 germinal center B-cell-like (GCB) DLBCLs. All cases of CD5+ DLBCL were classified as ABC DLBCLs. The classifier based on gene expression used in a supervised analysis correctly identified CD5 expression in the DLBCL and ABC DLBCL samples. The gene most relevant to CD5 expression was SH3BP5. The enriched GO categories in the CD5+ ABC DLBCL signature gene set were multicellular organismal signaling, transmission of nerve impulse, and synaptic transmission. This present study, which includes the largest reported number of patients with CD5+ DLBCL, confirmed that most CD5+ DLBCLs are ABC DLBCLs, suggesting that therapeutic strategies for ABC DLBCL may be effective for the treatment of CD5+ DLBCL. Our CD5+ ABC DLBCL signature gene set may provide insights into the cause of the high frequency of CNS relapse in CD5+ DLBCL.

2015-05-19 | GSE66770 | GEO

Integrative Analysis of a series of newly diagnosed Diffuse Large B-cell Lymphomas (DLBCLs)

2012-09-12 | GSE34171 | GEO

Gene expression profiling of diffuse large B-cell lymphomas supervised by CD5 expression

2015-05-19 | E-GEOD-66770 | biostudies-arrayexpress

Role of microRNAs and microRNA machinery in the pathogenesis of Diffuse large B-cell Lymphomas

Project description:We performed miRNA expression profiling in a series of de novo DLBCLs, transformed DLBCLs and non-neoplastic lymph nodes using a microarray approach. Significant differentially expressed miRNAs among groups were identified using SAM analysis. Agilent microarray platform containing 470 miRNAs was used to determine miRNA expression profiles in 45 DLBCL cases (32 de novo and 13 transformed) and 10 lymph nodes. To validate the microarray platform, the expression levels of selected miRNAs were evaluated using qRT-PCR.

2014-01-27 | E-GEOD-42906 | biostudies-arrayexpress

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma

Project description:MCL1 is an anti-apoptotic member of the BCL2 family that is deregulated in various solid and hematological malignancies. However, its role in the molecular pathogenesis of diffuse large B-cell lymphoma (DLBCL) is unclear. We analyzed gene expression profiling data from 350 DLBCL patient samples and detected that activated B-cell-like (ABC) DLBCLs express MCL1 at significantly higher levels compared to germinal center B-cell-like (GCB) DLBCL patient samples (p=2.7 x 10(-10)) [PMID 23257783]. Immunohistochemistry confirmed high MCL1 protein expression predominantly in ABC DLBCL in an independent patient cohort (n=249; p=0.001). To elucidate molecular mechanisms leading to aberrant MCL1 expression, we analyzed array comparative genomic hybridization (aCGH) data of 203 DLBCL samples [GSE11318] and identified recurrent chromosomal gains/amplifications of the MCL1 locus that occurred in 26% of ABC DLBCLs. In addition, aberrant STAT3 signaling contributed to high MCL1 expression in this subtype. Knockdown of MCL1 as well as treatment with the BH3-mimetic obatoclax induced apoptotic cell death in MCL1 positive DLBCL cell lines. In summary, MCL1 is deregulated in a significant fraction of ABC DLBCLs and contributes to therapy resistance. These data suggest that specific inhibition of MCL1 might be utilized therapeutically in a subset of DLBCLs. This GEO dataset is comprised of aCGH measurements for DLBCL cell lines, which are used in the above-mentioned paper. Cell lines were measured against the DNA of a healthy male donor who in turn was measured against a pool of healthy DNAs to correct for individual CNVs of the donor.

2013-01-04 | E-GEOD-43272 | biostudies-arrayexpress

Massive Transcriptional Perturbation in Subgroups of Diffuse Large B-cell Lymphomas

Project description:Based on the assumption that molecular mechanisms involved in cancerogenesis are characterized by groups of coordinately expressed genes, we developed and validated a novel method for analyzing transcriptional data called Correlated Gene Set Analysis (CGSA). Using 50 extracted gene sets we identified three different profiles of tumors in a cohort of 364 Diffuse large B-cell (DLBCL) and related mature aggressive B-cell lymphomas other than Burkitt lymphoma. The first profile had high level of expression of genes related to proliferation whereas the second profile exhibited a stromal and immune response phenotype. These two profiles were characterized by a large scale gene activation affecting genes which were recently shown to be epigenetically regulated, and which were enriched in oxidative phosphorylation, energy metabolism and nucleoside biosynthesis. The third and novel profile showed only low global gene activation similar to that found in normal B cells but not cell lines. Our study indicates novel levels of complexity of DLBCL with low or high large scale gene activation related to metabolism and biosynthesis and, within the group of highly activated DLBCLs, differential behavior leading to either a proliferative or a stromal and immune response phenotype. 72 samples from normal cells and lymphoma cell lines including: 8 samples of naÃ¯ve B cells, 13 samples of germinal center (GC) B cells, 9 samples of postGC B cells, 10 tissue samples of tonsils and 32 samples of 28 different lymphoma cell lines were hybridized to HGU133A Affymetrix GeneChips.

2013-11-01 | E-GEOD-43677 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data